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Abstract: Low levels of paraoxonase 1 (PON1) have been associated with the development of several
pathological conditions, whereas high levels have been shown to be anti-atherosclerotic in mouse
models. These findings suggest that PON1 could be a good surrogate biomarker. The other members
of the family, namely PON2 and PON3, the role of which has been much less studied, deserve
more attention. This paper provides a systematic review of current evidence concerning dietary
supplements in that regard. Preliminary studies indicate that the response to dietary supplements
may have a nutrigenetic aspect that will need to be considered in large population studies or in
clinical trials. A wide range of plant preparations have been found to have a positive action, with
pomegranate and some of its components being the best characterized and Aronia melanocarpa one of
the most active. Flavonoids are found in the composition of all active extracts, with catechins
and genistein being the most promising agents for increasing PON1 activity. However, some
caveats regarding the dose, length of treatment, bioavailability, and stability of these compounds in
formulations still need to be addressed. Once these issues have been resolved, these compounds
could be included as nutraceuticals and functional foods capable of increasing PON1 activity, thereby
helping with the long-term prevention of atherosclerosis and other chronic ailments.
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1. Introduction
Atherosclerosis is a chronic disorder of the arterial wall that starts with the formation of fatty
streaks and gradually evolves into atherosclerotic plaques [1]. Blood high-density lipoprotein (HDL)
levels are inversely correlated with atherosclerosis [2], with this beneficial effect of HDL being partly
attributed to its antioxidant properties mediated by paraoxonase 1 (PON1) [3,4] or platelet-activating
factor acetylhydrolase (PAF-AH) [5].
The PON1 gene, together with the genes for paraoxonases 2 and 3, form a gene family located
on the long arm of human chromosome 7 (7q21-22). PON1 is synthesized in the liver and secreted
into the serum as an HDL-associated protein [6]. As an antioxidant enzyme carried by HDL, it can
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hydrolyze lipid peroxide in lipoproteins as a result of its lipolactonase activity (Figure 1) [7,8], thereby
decreasing oxidative stress in serum lipoproteins, macrophages, and atherosclerotic lesions.Int. J. Mol. Sci. 2017, 18, 416 2 of 17 
 
 
Figure 1. Proposed biological role of paraoxonase 1. Adapted from [7], reproduced with permission 
from the American Society for Biochemistry and Molecular Biology. Although 5-hydroxy fatty acids 
are not frequent in normal physiology, they appear during inflammatory processes in macrophages 
and dendritic cells due to the action of cytochromes P-450 and 5′-lipooxygenase [9]. The extent to 
which they can esterify to form phosphatidylcholine is unknown. 
In light of the above, PON1 could be partly responsible for the anti-inflammatory and 
antiatherogenic properties of HDL molecules in blood [10]. Serum PON1 activity has been inversely 
associated with the risk of cardiovascular disease [11] and has been found to be decreased in several 
situations associated with atherosclerosis and oxidative stress [12]. Direct proof of its effects on 
atherosclerosis development was obtained from Pon1-deficient mice [13] and their counterparts 
overexpressing human PON1 gene [14]. As such, PON1 plays a major role in the protective role of 
HDL, and its status is considered to be one of the determinants that predispose people to coronary 
artery and other diseases [12]. Since PON1 undergoes inactivation by oxidative stress, its activity 
needs to be preserved [10]. Given the panoply of positive actions of PON1, pharmacological and 
nutritional modulation of PON1 activity and/or gene expression could constitute a useful approach 
to the prevention of cardiovascular and other diseases, such as diabetes, Alzheimer’s disease, chronic 
renal failure, and chronic liver impairment [15]. A recent review concerning PON1 and the 
Mediterranean diet analyzed the impact of this diet [16]. Dietary supplements also represent a new 
approach to enhancing population-based health [17]. In this work, we have searched for evidence of 
the effect of dietary supplements and plant extracts on PON1 by way of a strategy following 
systematic review guidelines [18]. As displayed in Figure 2, a search in PubMed using the keywords 
(paraoxonase and dietary supplements and paraoxonase and plant extracts), or 
(“aryldialkylphosphatase” [Mesh]) AND (“Plant Extracts” [Mesh] OR “Dietary Supplements” 
[Mesh]) identified 172 hits between November 1945 and 04 October 2016. The search was refined by 
eliminating duplicate documents. The 94 papers obtained were critically reviewed to verify whether 
they analyzed PON1 and dietary administration. Documents that failed to meet this criterion were 
excluded. Thus, this review covers the studies related to the effects of dietary supplements and PON1 
published in 90 papers. 
Figure 1. Proposed bi logical role of para xonase 1. Adapted from [7], reproduced with permission
from the American Society for Biochemistry and olec l r i l . lt 5-hydroxy fatty acids are
not frequent in ormal physiol gy, they appear during inflam atory processe in macrophages and
endritic cells due to the action f cytochromes P-450 and 5′-lipooxygenase [9]. The extent o which
they can esterify to form phos atidylcholine is unknow .
In light of the above, PON1 could be partly responsible for the anti-inflammatory and antiatherogenic
properties of HDL molecules in blood [10]. Serum PON1 activity has been inversely associated
with the risk of cardiovascular disease [11] and has been found to be decreased in several situations
associated with atherosclerosis and oxidative stress [12]. Direct proof of its effects on atherosclerosis
development was obtained from Pon1-deficient mice [13] and their counterparts overexpressing
human PON1 gene [14]. As such, PON1 plays a major role in the protective role of HDL, and its
status is considered to be one of the determinants that predispose people to coronary artery and
other diseases [12]. Since PON1 undergoes inactivation by oxidative stress, its activity needs to be
preserved [10]. Given the panoply of positive actions of PON1, pharmacological and nutritional
modulation of PON1 activity and/or gene expression could constitute a useful approach to the
prevention of cardiovascular and other diseases, such as diabetes, Alzheimer’s disease, chronic renal
failure, and chronic liver impairment [15]. A recent review concerning PON1 and the Mediterranean
diet analyzed the impact of this diet [16]. Dietary supplements also represent a new approach to
enhancing population-based health [17]. In this work, we have searched for evidence of the effect of
dietary supplements and plant extracts on PON1 by way of a strategy following systematic review
guidelines [18]. As displayed in Figure 2, a search in PubMed using the keywords (paraoxonase and
dietary supplements and paraoxonase and plant extracts), or (“aryldialkylphosphatase” [Mesh]) AND
(“Plant Extracts” [Mesh] OR “Dietary Supplements” [Mesh]) identified 172 hits between November
1945 and 04 October 2016. The search was refined by eliminating duplicate documents. The 94 papers
obtained were critically reviewed to verify whether they analyzed PON1 and dietary administration.
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Documents that failed to meet this criterion were excluded. Thus, this review covers the studies related
to the effects of dietary supplements and PON1 published in 90 papers.
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Figure 2. Flow chart displaying the steps followed to select the references considered. EndNote X7 
(Thomson Reuters: New York, NY, USA, 2016). * Some references may appear in more than one 
section of the review. 
2. PON1 and Nutrigenetics 
The interindividual variation in the response of PON1 activity to dietary supplements is partly 
influenced by genetic factors, such as polymorphisms in the APOE or PON1 genes, as indicated by 
two experimental studies. In the first study, administration of a diet containing 2 g/kg quercetin for 
six weeks resulted in lower hepatic mRNA and protein levels of PON1 in APOE4 than in APOE3 
transgenic mice. These results indicate that PON1 is differentially regulated in response to the APOE 
genotype [19]. The second study had a cross-over design and was intended to determine the effect of 
250 mL of antioxidant-rich orange plus 250 mL of blackcurrant juice and 15 mg vitamin E supplement 
for 28 days on PON1 activity, although no changes were observed in patients with peripheral arterial 
disease. However, a gene–diet interaction was observed between dietary treatment and the PON1 
genotype, with PON1 activity increasing after consumption of juices alone in patients carrying the 
PON1L55 allele [20]. 
3. Plant Preparations 
A great deal of experimental work has been carried out on the effect of different plants on PON1, 
with a large variety of models also having been tested. In this regard, mice and rats are the most 
widely used models for testing the effect of plant extracts. For example, Eucommia ulmoides Oliver leaf 
extract equivalent to 1% dried whole leaf (1.87 g of extract/kg of diet) was administered for six weeks 
to type 2 diabetic C57BL/KsJ-db/db mice. This extract elevated plasma PON1 activity compared with 
the control group [21]. A similar effect was observed by Saha et al., who reported that PON1 activity 
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(Thomson Reuters: New York, NY, USA, 2016). * Some references may appear in more than one section
of the review.
2. PON1 and Nutrigenetics
The interindividual variation in the response of PON1 activity to dietary supplements is partly
influenced by genetic factors, such as polymorphisms in the APOE or PON1 genes, as indicated by
two experimental studies. In the first study, administration of a diet containing 2 g/kg quercetin for
six weeks resulted in lower hepatic mRNA and protein levels of PON1 in APOE4 than in APOE3
transgenic mice. These results indicate that PON1 is differentially regulated in response to the APOE
genotype [19]. The second study had a cross-over design and was intended to determine the effect of
250 mL of antioxidant-rich orange plus 250 mL of blackcurrant juice and 15 mg vitamin E supplement
for 28 days on PON1 activity, although no changes were observed in patients with peripheral arterial
disease. However, a gene–diet interaction was observed between dietary treatment and the PON1
genotype, with PON1 activity increasing after consumption of juices alone in patients carrying the
PON1L55 allele [20].
3. Plant Preparations
A great deal of experimental work has been carried out on the effect of different plants on PON1,
with a large variety of models also having been tested. In this regard, mice and rats are the most widely
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used models for testing the effect of plant extracts. For example, Eucommia ulmoides Oliver leaf extract
equivalent to 1% dried whole leaf (1.87 g of extract/kg of diet) was administered for six weeks to type
2 diabetic C57BL/KsJ-db/db mice. This extract elevated plasma PON1 activity compared with the
control group [21]. A similar effect was observed by Saha et al., who reported that PON1 activity in
serum and liver increased after administration of an aqueous Murraya koenigii extract at doses of 75 and
150 mg/kg body weight in streptozotocin-induced diabetic mice [22]. Likewise, supplementation of
grape seed extracts recovered the decreased PON1 activity found in streptozotocin-induced diabetic
rats [23]. In contrast, El-Beshbishy et al. did not find recovery of PON1 activity upon administration of
a daily dose of 500 mg/kg of ethanolic extracts from Morus alba L. (Egyptian mulberry) root bark in
hypercholesterolemic rats [24].
Red wine polyphenol extract supplementation to the drinking water of heterozygous Cbs-deficient
mice (a murine model of hyperhomocysteinemia) for four weeks increased hepatic Pon1 expression
and hepatic and plasma PON1 arylesterase activities [25]. Administration of a 1.25% (w/w)
anthocyanin-rich extract from black elderberry (Sambucus nigra, 13% anthocyanins) containing cyanidin
3-sambubioside and cyanidin 3-glucoside (9.8% and 3.8%, w/w, respectively) significantly increased
serum PON1 arylesterase activity in 10-week-old male Apoe-deficient mice after six weeks [26]. In this
model, 0.05% dietary Chokeberry extract was also found to increase serum PON1 activity [27].
According to an analysis of doses used and the magnitude of the observed effect reflected in Table 1,
the Aronia melanocarpa (chokeberry) extract was the most effective at increasing PON1 activity. It has
been proposed that the phenolic compounds contained therein, especially anthocyanins, phenolic
acids, proanthocyanidins, and flavonols, might be involved in this effect.
When Jaiswal et al. explored the effect of onion extract and flavonoids (quercetin and catechin)
on the regulation of PON1 expression in male Wistar rats subjected to mercuric chloride-induced
oxidative insult, they observed that onion extract significantly attenuated the adverse effects of HgCl2
by upregulating PON1 activity. Quercetin and, to a lesser extent, catechin induced similar effects [28].
In this animal model, the administration of Aronia melanocarpa juice statistically restored the PON
activity of rats on a high-fructose and unsaturated fat diet [29]. Cornelian cherry, as a rich source of
phenolic compounds, had a stimulating effect on PON1 activity in both the brain tissue and plasma
of Wistar rats consuming control, high-fructose, and high-fat diets [30]. In rats with myocardial
ischemia, treatment with flaxseed in combination with exercise recovered the decreased PON1 and
HDL levels, whereas administration of flaxseed alone had no effect [31]. In a rat ischemia–reperfusion
model, significant decreases were observed in the serum PON1 levels of animals given ginsenoside
despite the decrease in malonyldialdehyde [32]. In contrast, the decrease of PON1 and arylesterase
activities in arthritis-induced rats was restored after treatment with soy protein and isoflavone
(genistein and daidzein) for 50 days [33]. Likewise, 2% (dry w/w) diet supplementation with pulp of
Euterpe oleracea Mart also increased PON1 activity in female Fischer rats fed standard chow (AIN-93 M)
or hypercholesterolemic (25% soy oil and 1% cholesterol) diets [34]. The inclusion of 28% avocado in
the diet increased PON1 activity in Wistar male rats [35].
Supplementation of the ethyl acetate extract of Vigna unguiculata leaves (150 mg/kg body weight)
normalized the decreased PON1 expression of rabbits fed a diet containing 1% cholesterol and 0.5%
cholic acid [36].
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Table 1. Plant preparations found to increase serum PON1 in different experimental designs.
Extract Experimental Model Dose Effect References
Eucommia ulmoides Oliver leaf Diabetic C57BL/KsJ-db/db mice 400 mg/kg bw ↑ 22% [21]
Murraya koenigii Streptozotocin-induced diabetic mice 150 mg/kg ↑ 105% [22]
Grape seed extracts Streptozotocin-induced diabetic rats 100 mg/kg ↑ 86% [23]
Red wine polyphenol extract Heterozygous Cbs-deficient mice 100 mg/kg ↑ 20% [25]
Sambucus nigra Apoe-deficient mice 200 mg/kg ↑ 20% [26]
Aronia melanocarpa Apoe-deficient mice 6 mg/kg ↑ 39% [27]
Onion extract Mercuric chloride-induced oxidative insult in male Wistar rats 20 mg/kg ↑ 30% [28]
Aronia melanocarpa Rats on a high-fructose and high-fat diet Not reported ↑ 65% [29]
Cornelian cherry Rats on a high-fructose and high-fat diets Not reported ↑ 45% [30]
Genistein Arthritic rats 20 mg/kg ↑ 230% [33]
Euterpe oleracea Mart Female Fischer rats on high-cholesterol, high-fat diets 2 mg/kg ↑ 60% [34]
Avocado Male Wistar rats 28 g/kg ↑ 33% [35]
Ilex paraguariensis Healthy volunteers 0.5 L of extract ↑ 10% [37]
Cranberry extract with vitamin C and zinc Healthy volunteers 2 g/day (300 mg/day) ↑ 67% [38]
Zingiber officinale Type 2 diabetic patients 3 g ↑ 28% [39]
Salvia miltiorrhiza Type 2 diabetic patients Not reported Increased PON1 activity [40]
Origanum onites Hyperlipidemic patients Not reported ↑ 14% [41]
bw: body weight.
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.
The influence of several compounds has been investigated in both human cell lines and human
subjects. In the former, HepG2 cells were treated with various concentrations of Graptopetalum paraguayense
extracts for 48 h, with those extracts prepared in 50% ethanol in water being found to be the most
effective at increasing PON1 arylesterase activity and gene expression [42]. In the latter approach,
PON1 activity was considered as a marker of antioxidant protection. In this regard, administration
of 0.5 L of Ilex paraguariensis extract (2–20 µL/mL), the polyphenol-rich beverage mate, to healthy
volunteers resulted in increased PON1 activity [37]. This action could be due to 5-caffeoylquinic
acid, which is the main compound in coffee, many fruits, and Ilex paraguariensis extracts, which
showed a concentration-dependent inhibition of HDL oxidation that was complete at 25 µmol/L [43].
Begcevic et al. found that administration of cranberry extract (2 g/day) and vitamin C plus zinc
(300 mg/day) to 31 healthy volunteers for four weeks induced a significant increase in PON1 activity
in nonsmokers [38]. However, the administration of 300 mg/day of phenolic compounds obtained
from French oak wood (Quercus robur) had no significant influence on glutathione levels and PON1
activities towards either arylester or lactone substrates despite a significant negative correlation
between paraoxonase lactonase activity and homocysteine levels in 20 healthy volunteers [44]
Ginger (Zingiber officinale) has been shown to contain biologically active compounds, including
gingerol, shogaol, paradol, and zingerone. In a double-blind, placebo-controlled, randomized clinical
trial, supplementation of 3 g of powdered ginger for three months improved PON1 activity in patients
with type 2 diabetes [39]. In this type of patients, a hydrophilic extract of Salvia miltiorrhiza administered
for 60 days also increased PON1 activity and the latter was accompanied by a decrease in oxidative
stress [40]. In mild hyperlipidemic patients, consumption of Origanum onites distillate significantly
increased serum paraoxonase and arylesterase activities and improved endothelial function [41]. These
observations point to the potential complementary role of dietary supplements in improving PON1
and their possible introduction into primary prevention of atherosclerosis. Moreover, the disparity
of experimental settings indicates that more comprehensive studies are required to establish the
protective effect of different plant preparations and limitations in terms of doses or pre-existing
pathological damage.
4. Pomegranate Juice
Pomegranate juice contains tannins and anthocyanins, some of which, including punicalagin,
punicalain, gallic acid, and urolithins A and B, are very powerful antioxidants [45]. For this reason,
the effects of pomegranate juice have been widely studied in a range of experimental settings [46–50].
As such, a special section will be devoted to this juice.
In patients with carotid artery stenosis, pomegranate juice consumption for a period of 12 months
resulted in an 83% increase in serum PON1 activity, together with a reduction in common carotid
intima-media thickness and systolic blood pressure. No further benefit was observed when a
longer administration regimen was followed [46]. Pomegranate juice consumption by diabetic
patients resulted in anti-oxidative effects on serum and macrophages, with an increase in PON1
activity that reached the values found for normal subjects. These effects could contribute to an
attenuation of atherosclerosis development in these patients [47]. In diabetic patients, HDL-associated
PON1 arylesterase, paraoxonase, and lactonase activity increased significantly after consumption of
Wonderful brand pomegranate juice (50 mL/day for four weeks). PON1 protein binding to HDL
was significantly increased, and the enzyme became more stable. A similar pattern was observed
in both male and female patients who consumed pomegranate polyphenol extract (5 mL/day for
six weeks), although to a lesser degree in the latter [51]. A higher dose (10 mL/day) pomegranate
extract for 12 weeks was found to increase PON1 in patients with active rheumatoid arthritis [48]. In
hemodialyzed patients, daily administration of 1000 mg of a purified pomegranate polyphenol extract
for six months increased PON1 activity [52]. Pomegranate juice, or its purified phenolic compounds
punicalagin, gallic acid, or ellagic acid, promote binding of a labeled recombinant PON1 to HDL
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in vitro [49]. Since the association of PON1 with high-density lipoprotein (HDL) stabilizes the enzyme,
these beneficial effects of pomegranate consumption on serum PON1 stability and activity could lead
to retardation of atherosclerosis. Pomegranate extracts administered to Apo-E deficient mice increased
serum PON1 activity, with whole fruit juice being more efficient than administration of aryls [50].
This extract has also been combined with others to improve its properties. Thus, the combination
of pomegranate with date extract, which is also a good source of phenolic compounds, has been tested
in Apoe-deficient mice. At a dose of 0.5 µmol/day/mouse of gallic acid equivalents, pomegranate
juice, Hallawi date extract, date seed extract, or a combination of them were tested for three weeks.
Consumption of the combination resulted in the highest increases in serum and aorta PON1 activities,
the latter of which was associated with a reduction in aortic lipid peroxide content [45].
5. Phenolic Compounds
Cinnamate is a widespread secondary metabolite of phenolic compounds synthesized by plants.
When two structurally related derivatives, namely 4-hydroxycinnamate and 3-(4-hydroxyphenyl)
propionic acid, were administered at a dose of 1.35 mmol/kg to male rats fed a high-cholesterol diet,
plasma PON1 activity was found to be higher in the cinnamate-derivative-supplemented groups than
in the control group [53].
Curcumin is a common dietary supplement that has been shown to induce PON1 transactivation
in Huh7 cells in a dose-dependent manner. However, dietary supplementation of female B6C3F1 mice
with curcumin (500 mg/kg diet) for two weeks did not increase hepatic Pon1 mRNA and protein levels.
In conclusion, curcumin may be a potent PON1 inducer in cultured cells in vitro, but not in the liver of
curcumin-fed mice because of its low concentrations in vivo [54]. This low bioavailability could be
due to its chemical instability at the extreme pH values found in the stomach and intestine.
Resveratrol is one of the best-studied phenolic compounds found in red wine, and its influence
has been tested in vitro and in vivo. Thus, incubation of HUH7 liver cells stably transfected with
PON1 in the presence of 10 and 25 µmol/L resveratrol significantly increased PON1 transactivation.
An ascorbic acid concentration of 1000 µmol/L slightly enhanced PON1 transactivation. Furthermore,
resveratrol induces PON1 protein levels in HUH7 cells, and this induction was not counteracted by
ascorbic acid [55].
To investigate the anti-atherogenic properties of resveratrol supplements (0.02% and 0.06%, w/w),
Apoe-deficient mice were used. Plasma PON activity was significantly higher in the group receiving
0.06% resveratrol compared to the control group, as was HDL concentration and the HDL/total
cholesterol ratio. Moreover, PON1 activity was negatively correlated with serum thiobarbituric acid
reactive substances (TBARS) concentration [56]. Resveratrol showed a different pattern in cystathionine
beta synthase-deficient mice, with a one-month administration of 0.001% resveratrol significantly
decreasing serum PON1 activity [57].
Several epidemiological studies have reported that consumption of flavonoids, which are polyphenolic
compounds available in plant-based foods, and especially catechins, might have a chemopreventive
effect against cancer and cardiovascular disease [58]. Given these findings, their effect on PON1
has also been tested. Thus, supplementation with naringenin, or its synthetic derivative naringenin
7-O-cetyl ether (0.73 mmol/kg diet), increased plasma PON1 activity in high-cholesterol-fed male
Sprague–Dawley rats [59]. In male Wistar rats receiving a 400 mg/kg dose of rutin for two weeks, the
hepatic activity of PON1 increased by 17% compared to controls [60]. In this animal model, Jaiswal et
al. showed that administration of quercetin, and to a lesser extent catechin, significantly attenuated
the adverse effects of HgCl2 by upregulating PON1 activity and protected against LDL oxidation and
lipid peroxidation [28]. A similar result was found by Mohammadshahi et al., who also observed a
recovery in the decreased PON1 activity in arthritic rats when administering soy isoflavones (genistein
and daidzein) for 50 days [33]. In hemodialyzed patients receiving catechins (455 mg/day), PON1
activity was higher than in patients with the placebo [61].
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Genistein was the most potent flavonoid in terms of PON1-inducing activity in stably transfected
Huh7 liver cells in comparison with other flavonoids. In contrast, dietary genistein supplementation
(2 g/kg diet over three weeks) in growing rats did not increase hepatic Pon1 mRNA and protein levels
or plasma PON1 activity. Thus, genistein may be a PON1 inducer in cultured hepatocytes in vitro,
but not in rats in vivo [62]. Plasma PON1 activity did not change after genistein was combined with
polysaccharide supplementation in postmenopausal Korean women. However, the activity of other
antioxidant enzymes, such as glutathione peroxidase, was significantly increased. These findings
suggest that this supplementation may improve antioxidant status in postmenopausal women, but not
in a PON1-dependent manner [63]. Due to the metabolism of these compounds by intestinal microbiota,
a wide range of biological responses associated with different microbiomes is to be expected. Thud,
daidzein may be transformed into equol, an isoflavandiol actin that acts as a non-steroidal estrogen [64].
The different effects of in vivo administration of genistein are therefore not surprising. Thus, while
Mohammadshahi et al. found a marked recovery in PON1 activity [33], Schrader et al. did not observe
any such changes [62]. However, there are major differences between these two papers despite using
the same animal model (rat), including dose (20 in the former vs. 1 mg/kg in the latter), length of
administration (50 vs. 22 days), and presence or absence of a pathological condition decreasing PON1
activity. According to our comparison of dose and observed effect, this isolated compound may have a
noticeable effect on PON1 in vivo (Table 2). The change induced by tea catechins is also remarkable.
Thus, flavonoids are considered to be important agents for increasing PON1 activity.
Table 2. Effect of phenolic compounds on PON1 in different in vivo experimental settings.
Compound Experimental Model Dose Effect References
3-(4-Hydroxyphenyl)
propionic acid Rats fed a high-cholesterol diet 1.35 mmol/kg ↑ [53]
Resveratrol Apoe-deficient mice 12 mg/kg ↑75% [56]
Flavonoids
Naringenin High-cholesterol-fed Sprague–Dawley rats 4 mg/kg ↑ 37% [59]
Rutin Wistar rats 400 mg/kg ↑ 17% [60]
Quercetin HgCl2 treated Wistar rats 20 mg/kg ↑ 20% [28]
Genistein Arthritic rats 20 mg/kg ↑ 230% [33]
Tea catechins Hemodialyzed patients 6 mg/kg ↑ 150% [61]
Anthocyanins Hypercholesterolemic subjects 4 mg/kg ↑ 22% [65]
The effect of anthocyanins on HDL–PON1 activity and cholesterol efflux capacity was evaluated
in hypercholesterolemic subjects, who received 160 mg of anthocyanins twice daily for 24 weeks
in a double-blind, randomized, placebo-controlled trial. Anthocyanin consumption significantly
increased HDL cholesterol and HDL–PON1 activity, with negative correlations being established
between the latter and HDL lipid hydroperoxides. Furthermore, a strongly positive correlation was
noted between HDL–PON1 activity and cholesterol efflux capacity both before and after adjustment for
HDL cholesterol and APOA1 in anthocyanin-treated subjects. These results indicate that HDL–PON1
activity might participate in the antioxidant and cholesterol efflux properties of HDL [65].
6. Vitamins
Two vitamins, namely C and E, have received particular attention. Thus, supplementation with
vitamin C provoked an increase in PON1 activity and a decrease in advanced glycation products and
lipid hydroperoxide levels in hemodialysis patients. These findings provide further evidence that lipid
peroxidation and impairment of the antioxidant system in the plasma of these patients may play a role
in renal disease and suggest that evaluation of PON1 activity could represent a useful approach for
monitoring antioxidant treatment and new dialysis therapies [66]. In a similar study, serum PON1
activity was found to decrease from preconception to labor in 35 women. A direct association between
vitamin C intake and PON1 at week 32 was observed, suggesting that vitamin C supplementation
in pregnant women deserves further attention [67]. However, a vitamin supplement (200–300 mg
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calcium, 15 mg zinc, 17 mg iron, 400 µg folic acid, 400 IU vitamin D, 70 mg vitamin C, 3 mg thiamine,
2 mg riboflavin, 20 mg niacin, 6 µg vitamin B12, and 10 mg vitamin E) had no effect on the oxidative
stress status of healthy pregnant women [68]. When Begcevic et al. analyzed the effects of vitamin
C and zinc (300 mg/day) on serum PON1 activity in 31 healthy volunteers over four weeks, they
observed a significant increase in PON1 activity in nonsmokers after the intervention [38]. Using the
commercial preparation ALA nerv®, which contains essential fatty acids, vitamins, and oligo-elements,
Manolescu et al. reported an increase in PON1 lactonase activity in 28 post-acute stroke patients
receiving two pills/day for two weeks [69].
Vitamin E supplementation increased the serum paraoxonase and arylesterase activities of
propylthiouracil-induced hypothyroidism in male Sprague–Dawley rats [70]. This vitamin also
recovered the decrease in PON1 induced by exercise in untrained dogs [71]. Likewise, oral
supplementation of vitamin E (200 mg/day) prevented the exercise-induced decrease in PON1/Aryl
esterase activity in basketball players [72]. This vitamin has been combined with other agents to
improve PON1 properties. Thus, oral supplementation with vitamin E (300 mg/kg) and sodium
selenite (0.5 mg/kg) once a day for four weeks in streptozotocin-induced diabetic rats restored PON1
activity to the levels observed in healthy animals [73]. The administration of 0.2% vitamin E together
with 0.02% ferulic acid in Apoe-deficient mice also increased hepatic PON1 [74]. Other combinations,
containing vitamin C, zinc gluconate, and selenium, have been prepared and tested in elite women
athletes. Significant positive correlations between antioxidant defense and lipid status were found,
with a significant positive correlation between PON1 activity toward paraoxon and LDL-cholesterol,
but only before training and supplementation. Free-radical generation before and after training
did not affect paroxonase activity, and no significant correlation was found with oxidative stress
parameters [75,76].
7. Protein and Amino Acids
Relatively little attention has been devoted to the influence of the quality of proteins or amino
acids on PON1 activity. In this regard, commercial whey protein was found to improve PON1 activity
in rats compared with casein [77]. Administration of the amino acid derivative L-carnitine recovered
the exercise-induced decrease in PON1 in sedentary people [78], although the non-proteinogenic
amino acid taurine was found to be more active. Thus, serum paraoxonase and arylesterase activities
were increased in a dose-dependent manner in taurine-treated hypothyroid Sprague–Dawley rats,
and taurine concentrations were positively correlated with enzyme activities [79].
8. Dietary Lipids
8.1. Cholesterol Supplementation
Administration of cholesterol (3.6 g/kg/day) for three months decreased hepatic PON1 activity
in Sprague–Dawley rats [80]. Similar results were obtained by our group using male Apoe-deficient
mice and with lower cholesterol intakes (1 g/kg/day). We also observed a selective sex response, with
females being more resistant to the action of this compound [81].
8.2. Polyunsaturated Fatty Acids
A combination of red yeast rice and rice bran oil increased serum PON1 levels in male
Sprague–Dawley rats compared to those receiving a hypercholesterolemic diet alone [17].
The ALA nerv® nutritional preparation, which contains linoleic acid, α-lipoic acid, and gamma
linoleic acid along with other vitamins and selenium, provoked a significant increase in PON1 lactonase
activity when evaluated in post-acute stroke patients (two pills/day for two weeks) [69].
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Fish Oil
The influence of supplementation with this oil on PON1 has been widely studied. Thus,
an increase in serum PON1 activity associated with HDL lipid composition changes was observed in
obese rats receiving 20% sardine byproduct oil [82], whereas dietary administration ofω-3 fatty acids
(EPA + DHA, 1.2:1) at doses of 0.3 or 1 g/kg body weight for four weeks in rats decreased the activity of
PON1. A similar decrease was observed in a postprandial approach involving fish oil supplementation
in Balb/C mice associated with oxidative stress. This effect was corrected in PON1-transgenic mice,
thereby suggesting a PON1 lipase-like activity on chylomicron triacylglycerols [10]. However, a higher
dose of ω-3 fatty acids resulted in a 45% increase in PON1 activity [83]. Hepatic PON1 activity
significantly increased in fish-oil-treated rats [84].
In a double-blind randomized controlled trial carried out in 90 female patients with rheumatoid
arthritis receiving 1 g of fish oil or a placebo in addition to conventional treatment, fish oil supplementation
significantly increased PON1 activity [85]. Further positive evidence was obtained when comparing
the HDL proteome before and after five weeks of aω-3 PUFA-supplemented diet in smoker subjects.
In that study, Burillo et al. reported that the supplement increased PON1 protein, thereby suggesting
a positive change in the functionality of the HDL molecule [86]. Contrary to these findings, in a
randomized controlled trial, women with iron deficiency anemia randomly assigned to receive 500 mg
of DHA supplement or placebo with an iron tablet, once daily for 12 weeks, showed no significant
differences in terms of serum PON1 concentration [87]. Four years ago, Whelan et al. reviewed
the effect of stearidonic acid, a highly unsaturated (n-3) PUFA that is effectively metabolized to
eicopentaenoic acid, and concluded that its administration is a favorable modulator of PON1 [88].
8.3. Olive Oil and Coenzyme Q10
In subjects receiving 20 mL of extra virgin olive oil supplemented with 20 or 40 mg of coenzyme
Q10, a positive correlation was observed between concentration of the coenzyme in HDL and PON-1
activity, with a lower susceptibility of LDL to peroxidation also being found [89].
8.4. Hydrocarbons
Administration of squalene at a dose of 1 g/kg for 11 weeks showed decreased reactive oxygen species
in lipoprotein fractions irrespective of the animal background (wild-type, Apoa1-, and Apoe-deficient
mice) and caused a specific increase in HDL-cholesterol levels, accompanied by an increase in PON1.
The increases in HDL–PON1 resulted in decreased plasma malondialdehyde levels depending on the
presence of apolipoprotein A1. The phenotype related to apolipoproteins A1 and E may be particularly
relevant [90].
Astaxanthin is a carotenoid pigment present in crustaceans and salmon. In soccer players, there
was a significant interaction between the effect of astaxanthin supplementation and training on PON1
activity. Thus, PON1 activity increased in the supplemented group after 90 days, as did the thiol
content. As such, astaxanthin was proposed to improve PON1 activity by protecting free thiol groups
against oxidative modification [91].
9. Oligoelement Supplementation
Two oligoelements, namely selenium and zinc, have received particular attention. With regard to the
former, four months of selenium administration at 1 mg/kg diet improved the high-fat-diet-mediated
reduction of serum PON1 enzyme activity and PON1 protein levels, with no changes in hepatic mRNA
expression, in male Sprague–Dawley rats [92]. However, dietary supplementation with 1 or 3 mg
Se/kg diet, with or without 250 or 750 mg vitamin E/kg diet, did not completely abolish the effects of
MeHg as regards a reduction in PON1 activity [93]. Inclusion of ALA nerv®, a nutritional supplement
containing selenium (two pills/day for two weeks), resulted in a significant increase in PON lactonase
activity when evaluated in post-acute stroke patients [69].
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Zinc administration partially reversed the significant decrease in PON1 induced in rats by
administration of carbon tetrachloride [94] and in mice by Schistosoma mansoni infection [95]. When
tested in hemodialysis patients, a 100 mg/day zinc supplementation for two months significantly
increased serum levels of PON activity [96]. In 31 healthy volunteers exposed to commercially
available preparations of vitamin C and zinc (300 mg/day) for four weeks, Begcevic et al. also reported
a significant increase in PON1 activity in nonsmokers after the intervention [38]. In contrast, mineral
(15 mg zinc, 17 mg iron) and vitamin supplementation failed to increase PON1 activity in pregnant
women [68]. It has also been proposed that copper supplements may exert a protective effect on PON1,
assuming that a copper deficiency decreases this enzyme [97]. The results suggest that the doses
and/or exclusion criteria for subjects (smokers or non-smokers) and types of patients may be crucial
in the outcome and should be carefully tested.
10. Others
Beta glucan supplementation increased PON1 activities in the brain and sciatic nerve of
streptozotocin-induced diabetic rats [98]. Dietary supplements of symbiotics (Perfectin) and probiotics
(Protexin) induced increased PON1 activity in White Leghorn chicken [99]. Supplementation with the
commercial formulas Build-up (Nestle) and Maxijul (SHS Ltd.) for eight weeks failed to recover the
decreased PON activity observed in frail elderly patients [100].
11. Conditions Negatively Affecting PON1 Activity
Several dietary supplements have been identified to have a negative influence on PON1 activity,
including quercetin, vitamin, and amino acid supplementations, or at least in certain genetic
backgrounds, animal models, or pathological conditions. As mentioned in Section 2, the response of
PON1 activity to dietary supplements is modified by APOE gene polymorphisms. In this regard, the
administration of a diet containing quercetin resulted in lower hepatic mRNA and protein levels of
PON1 in APOE4 than in APOE3 transgenic mice [19]. Moreover, vitamin E supplementation in high-fat
and -cholesterol diets significantly reduced serum PON1 activity in baboons [101]. Supplementation
of the amino acid derivative betaine had no effect on plasma PON1 paraoxonase or arylesterase
activities in hyperhomocysteinemic mice. However, betaine- and methionine-restricted diets decreased
paraoxonase activity in this type of human patient [102].
12. PON2
Paraoxonase 2 (PON2), a member of the paraoxonase gene family, has been shown to protect
macrophages against oxidative stress. Thus, incubation of J774A.1 macrophages with pomegranate
juice (0–50 µM of total polyphenols) increased expression (mRNA, protein) and PON2 activity,
and reduced macrophage oxidative status, in a dose-dependent manner. These effects could
be attributed to punicalagin and gallic acid, which are the main phenolic components of this
juice. The polyphenol-induced upregulation of PON2 was inhibited by using the peroxisome
proliferator-activated receptor gamma (PPARγ) inhibitor GW9662. Similarly, the PPARγ ligand
rosiglitazone stimulated macrophage PON2 expression in a dose-dependent manner. Inhibition of
AP-1 activation with SP600125 attenuated pomegranate juice-induced upregulation of PON2. Thus, the
pomegranate juice stimulatory effect on macrophage PON2 expression was associated with activation
of the transcription factors PPARγ and AP-1 [103]. Consumption of whole fruit juice and peels, either
as a liquid or powder extract, resulted in a significant increase in PON2 lactonase activity in mice
macrophages [50]. Another phenolic-rich plant has been tested as regards its ability to modulate
PON2. Thus, in vitro incubation of THP-1 macrophages with yerba mate (Ilex paraguariensis) extract
increased PON2 gene expression at concentrations ranging from 1 to 3 µmol/L, whereas higher
concentrations only increased the activity. Increased PON2 gene expression and activity were observed
in the monocytes of healthy women 2 h after yerba mate consumption. However, when this extract
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was administered for seven days, the increase in gene expression was not reflected in the activity of
either monocytes or monocyte-derived macrophages [104].
13. PON3
Despite having an important protective role against atherosclerosis, no studies have been found
regarding dietary regulation of the third member of this family [6].
14. Conclusions and Outlook
A wide range of experimental evidence indicates that increasing PON1 and PON2 activity may
decrease oxidative stress and contribute to delaying the outcome of chronic diseases or mitigating
their impact on quality-of-life in patients. The search for plant extracts that are able to modulate
these activities is a highly active field of research, as reflected in this review. Given the tremendous
amount of work required to characterize planetary diversity in this regard, this field will undoubtedly
last for many more years. Complete chemical characterization of these plant extracts is an urgent
and demanding task as regards both identifying the target molecule and determining the matrix
that protects the active component. High-throughput screening will need to be carried out in cell
culture for obvious reasons of efficiency and animal welfare. To date, pomegranate juice has been
well characterized, and Aronia melanocarpa extract seems very promising. The translation of these
more promising findings into in vivo settings needs to be done carefully, paying special attention
to formulation and stability, doses, length of administration, and selection of the experimental
model. Once these aspects have been resolved, a wide range of formulations can be envisioned
for nutraceuticals and functional foods to enhance the protective role of paraoxonases.
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